March 2026
Psychedelic-assisted therapy
What March 2026's 9 new studies found, synthesized from the papers below. All Psychedelic-assisted therapy research →
The synthesis
Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psychedelic-assisted therapy, psychedelic therapy, assisted psychotherapy, drug-assisted therapy, then ranked by relevance.
Research in March 2026 indicates that psychedelic-assisted therapy (PAT) is being explored for a range of conditions including substance use disorders, PTSD, depression, and existential distress, with qualitative studies highlighting clinician and patient support alongside concerns about implementation, safety, and equity. The evidence is largely qualitative or review-based, with no new large-scale controlled trials reported, and key limitations include small sample sizes, lack of generalizability, and unresolved methodological issues such as blinding and safety monitoring.
Confidence in the evidence
Low-Moderate- Most studies are qualitative (e.g., focus groups, interviews) with small sample sizes (9-30 participants), limiting generalizability.
- One review (article_id 25110) summarizes RCT evidence for MDMA-AT but notes FDA rejection due to insufficient evidence and methodological flaws.
- Two scoping reviews (article_id 27286, 27287) highlight promising early findings but call for further research, indicating inconsistent or preliminary evidence.
- No new RCTs or meta-analyses are reported; the evidence base remains dominated by qualitative and theoretical work.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Unlocking 'stuckness' and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic-assisted therapy for substance use and mental health problems. 2026 | qualitative | 18 | Unclear | Clinicians and service leaders provided perspectives on psilocybin-assisted therapy for co-occurring depression and alcohol use disorder, but the abstract does not state a clear direction of effect. |
| “You can only take your clients as far as you’ve been yourself”: examining the intersections between psychedelic-assisted therapy, lived-living experience, and clinical practice 2026 | qualitative | 20 | Supports | Psychologists viewed lived-living experience with psychedelics as a valuable addition to PAT training, enhancing empathy and therapeutic rapport. |
| State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder 2026 | review | Mixed | MDMA-AT for PTSD shows promising outcomes in RCTs but was declined FDA approval due to insufficient evidence, with limitations including poor blinding and lack of active comparators. | |
| MDMA-assisted psychotherapy in major depression: critical considerations for clinical translation: commentary, Kvam et al. 2026 | commentary | Unclear | This commentary discusses critical considerations for clinical translation of MDMA-assisted psychotherapy for major depression, but no specific findings are reported. | |
| Psychedelic therapy and postpartum depression: priorities and prospects 2026 | review | Supports | Psychedelic therapy is a promising transdiagnostic strategy for PPD, but further research is needed to determine efficacy and safety profiles. | |
| A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations 2026 | scoping review | 410 | Supports | Mystical-type experiences are associated with reduced anxiety and depression symptoms in psychedelic therapy trials, but patterns may differ between populations. |
| A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program. 2026 | observational | 30 | Supports | A real-world ketamine-assisted psychotherapy program in palliative care was feasible and safe, with patients completing a median of 1.5 medicine sessions. |
| Views on Psychedelic-Assisted Therapy for Substance Use Disorders from Individuals with Opioid Use Disorder and a History of Injection-Related Infections: A Qualitative Study. 2026 | qualitative | 17 | Supports | Participants generally supported PAT for SUD, citing potential for insights and openness to recovery, but raised concerns about adverse effects and relapse. |
| Exploring barriers and opportunities for Black, Indigenous, and People of Color (BIPOC) therapists in psychedelic-assisted therapy: A qualitative study 2026 | qualitative | 18 | Mixed | BIPOC therapists identified opportunities for enhancing diversity and culturally attuned care in PAT, but also barriers such as financial inaccessibility and exclusionary training environments. |
Clinicians and service leaders provided perspectives on psilocybin-assisted therapy for co-occurring depression and alcohol use disorder, but the abstract does not state a clear direction of effect.
qualitative Sample size: 18
Psychologists viewed lived-living experience with psychedelics as a valuable addition to PAT training, enhancing empathy and therapeutic rapport.
qualitative Sample size: 20
MDMA-AT for PTSD shows promising outcomes in RCTs but was declined FDA approval due to insufficient evidence, with limitations including poor blinding and lack of active comparators.
review
This commentary discusses critical considerations for clinical translation of MDMA-assisted psychotherapy for major depression, but no specific findings are reported.
commentary
Psychedelic therapy is a promising transdiagnostic strategy for PPD, but further research is needed to determine efficacy and safety profiles.
review
Mystical-type experiences are associated with reduced anxiety and depression symptoms in psychedelic therapy trials, but patterns may differ between populations.
scoping review Sample size: 410
A real-world ketamine-assisted psychotherapy program in palliative care was feasible and safe, with patients completing a median of 1.5 medicine sessions.
observational Sample size: 30
Participants generally supported PAT for SUD, citing potential for insights and openness to recovery, but raised concerns about adverse effects and relapse.
qualitative Sample size: 17
BIPOC therapists identified opportunities for enhancing diversity and culturally attuned care in PAT, but also barriers such as financial inaccessibility and exclusionary training environments.
qualitative Sample size: 18
Points of agreement
- Qualitative studies consistently show that clinicians, patients, and stakeholders view PAT positively for various conditions, including substance use disorders and mental health issues.
- Reviews agree that PAT shows promise for conditions like PTSD, depression, and existential distress, but emphasize the need for more rigorous research.
- There is consensus that implementation challenges exist, including training, safety, and equity concerns.
Conflicts
- While some studies (e.g., article_id 27951, 30520) highlight strong support for PAT, others (e.g., article_id 25110) note that regulatory bodies have rejected approval due to insufficient evidence, indicating a gap between perceived benefits and empirical validation.
- The role of mystical-type experiences in therapeutic outcomes is supported (article_id 27286), but variability in response across populations suggests potential conflicts in mechanisms.
Gaps
- Durability of treatment effects is not addressed in any of the provided studies.
- Blinding and active comparator conditions remain unresolved, as noted in article_id 25110.
- Safety monitoring and long-term adverse effects are inadequately studied, especially in special populations like postpartum women (article_id 27287) and those with OUD (article_id 30520).
- Generalizability is limited due to small, non-diverse samples and lack of large-scale RCTs.
- Implementation frameworks for integrating PAT into routine care are scarce, as highlighted in article_id 30120.